Odem’s scope

 

Approximately 15% of all heart failure (HF) patients suffer from cardiac desynchrony, typically manifested by impaired activation and contraction of the left ventricle. This phenomenon deforms the normal cardiac contraction and results in impaired cardiac pumping. Patients with cardiac desynchrony suffer from progressive deterioration in their quality of life and increased mortality.  

 

The current treatment for cardiac desynchrony is based on cardiac pacing by a special pacemaker and leads setup that synchronize the contraction of the right and left ventricles. This treatment, termed ‘cardiac resynchronization therapy’ (CRT) was found to improve cardiac pumping. However, the current CRT approach suffers from limitations, and fails in about 40% of the patients.

 

Odem Medical  is developing a new approach and technology for synchronizing the contraction of the cardiac chambers. The products we presently develop will simplify and optimize the treatment for patients suffering from cardiac desynchrony.

A view from our window;

 the Jordan Valley and the Sea of Galilee

 

Odem was established as a startup company at 2006. The company operates at Meytag High Tech Venture Technological Incubator (www.meytag.co.il).

 

 

Odem’s Management Team:

Dror Frank, CEO

Gideon Meiry, PhD, Founder & CTO